Bioscience trends最新文献_第8页

Conversion therapy followed by surgery and adjuvant therapy improves survival in Barcelona C stage hepatocellular carcinoma - A propensity score-matched analysis. 转换治疗后的手术和辅助治疗提高了巴塞罗那C期肝细胞癌的生存率-倾向评分匹配分析。

IF 5 4区生物学

Bioscience trends Pub Date : 2025-09-17 Epub Date: 2025-07-26 DOI: 10.5582/bst.2025.01162

Yinbiao Cao, Liru Pan, Zikun Ran, Wenwen Zhang, Junfeng Li, Xuerui Li, Tianyu Jiao, Zhe Liu, Tao Wan, Haowen Tang, Shichun Lu

{"title":"Conversion therapy followed by surgery and adjuvant therapy improves survival in Barcelona C stage hepatocellular carcinoma - A propensity score-matched analysis.","authors":"Yinbiao Cao, Liru Pan, Zikun Ran, Wenwen Zhang, Junfeng Li, Xuerui Li, Tianyu Jiao, Zhe Liu, Tao Wan, Haowen Tang, Shichun Lu","doi":"10.5582/bst.2025.01162","DOIUrl":"10.5582/bst.2025.01162","url":null,"abstract":"Conversion therapy with a combination of tyrosine kinase inhibitor and anti-programmed death-1 antibody sequential surgery and postoperative adjuvant therapy has shown improved survival benefits in patients with Barcelona C stage (BCLC-C) hepatocellular carcinoma (HCC). We aimed to compare the survival benefits in a retrospective cohort of patients with BCLC-C HCC who underwent surgery after conversion therapy with adjuvant therapy and surgery alone. The conversion therapy group was derived from a prospective clinical study, and from January 2015 to September 2023, we selected patients diagnosed with BCLC-C HCC who underwent liver resection at Chinese PLA General Hospital as the surgical group. The primary endpoint in the comparison of survival benefits between conversion therapy and surgery-alone groups was recurrence-free survival. Propensity score matching was applied to reduce any potential bias in the study. By the end of follow-up, the conversion therapy group mRFS was 37.8 months, with postoperative 1-, 2- and 3-year RFS rates of 66.8%, 54.6%, and 48.3%. In the surgery group, the mRFS was 3.0 months, and postoperative 1- , 2- and 3-year RFS rates of 22.4%, 17.5%, and 15.0%, respectively. On multivariable Cox regression analyses, conversion therapy significantly reduced HCC-related mortality and HCC recurrence rates compared with surgery alone. For BCLC-C HCC patients, conversion therapy with adjuvant therapy is in relationship with increased survival in comparison with surgery alone.","PeriodicalId":8957,"journal":{"name":"Bioscience trends","volume":" ","pages":"432-444"},"PeriodicalIF":5.0,"publicationDate":"2025-09-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144727748","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Survival benefit of adjuvant chemotherapy and individualized prognosis in resected cHCC-CCA. 辅助化疗对切除cHCC-CCA患者的生存获益及个体化预后。

IF 5 4区生物学

Bioscience trends Pub Date : 2025-09-17 Epub Date: 2025-07-16 DOI: 10.5582/bst.2025.01178

Bo Sun, Yimeng Wang, Ruyu Han, Yuren Xia, Meng Zhao, Liyu Sun, Xiaochen Ma, Tianqiang Song, Xiangdong Tian, Wenchen Gong, Lu Chen

{"title":"Survival benefit of adjuvant chemotherapy and individualized prognosis in resected cHCC-CCA.","authors":"Bo Sun, Yimeng Wang, Ruyu Han, Yuren Xia, Meng Zhao, Liyu Sun, Xiaochen Ma, Tianqiang Song, Xiangdong Tian, Wenchen Gong, Lu Chen","doi":"10.5582/bst.2025.01178","DOIUrl":"10.5582/bst.2025.01178","url":null,"abstract":"Combined hepatocellular-cholangiocarcinoma (cHCC-CCA) is a rare malignancy with poor prognosis and unclear benefit from adjuvant chemotherapy. To identify the appropriate candidates for postoperative adjuvant chemotherapy in cHCC-CCA, we developed a prognostic model to predict patient outcomes and stratify populations accordingly. This retrospective study included 75 cHCC-CCA patients treated at Tianjin Medical University Cancer Institute and Hospital from 2009 to 2019. Prognostic factors were identified via univariate and multivariate Cox regression. Model performance was assessed using ROC curves, calibration plots, and decision curve analysis. Propensity score matching (PSM) was applied to reduce bias. Adjuvant chemotherapy significantly improved overall survival (OS) in Kaplan-Meier (p = 0.029) and PSM analyses (p = 0.0011). Five independent prognostic factors were identified: macrovascular invasion, lymph node metastasis, the largest tumor size >5 cm, the high expression of CD8, and the high expression of FOXP3. The nomogram showed good predictive performance. Among high-risk patients stratified by the nomogram, those receiving adjuvant chemotherapy had longer OS (p = 0.013), while no significant benefit was observed in the low-risk group (p = 0.084). Adjuvant chemotherapy improves postoperative survival in cHCC-CCA. The nomogram provides individualized risk stratification and may inform treatment decisions.","PeriodicalId":8957,"journal":{"name":"Bioscience trends","volume":" ","pages":"421-431"},"PeriodicalIF":5.0,"publicationDate":"2025-09-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144648430","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Radiotherapy enhances triple therapy for conversion and survival in patients with unresectable hepatocellular carcinoma with portal vein tumor thrombus. 放疗提高三联疗法对不可切除的肝癌合并门静脉肿瘤血栓患者的转归和生存率。

IF 5 4区生物学

Bioscience trends Pub Date : 2025-09-17 Epub Date: 2025-08-04 DOI: 10.5582/bst.2025.01170

Ying Zhou, Minghong Yao, Tianfu Wen, Chuan Li

{"title":"Radiotherapy enhances triple therapy for conversion and survival in patients with unresectable hepatocellular carcinoma with portal vein tumor thrombus.","authors":"Ying Zhou, Minghong Yao, Tianfu Wen, Chuan Li","doi":"10.5582/bst.2025.01170","DOIUrl":"10.5582/bst.2025.01170","url":null,"abstract":"Triple therapy (TT), consisting of transarterial chemoembolization, immune checkpoint inhibitors, and tyrosine kinase inhibitors, is recommended as a conversion therapy for patients with unresectable hepatocellular carcinoma (uHCC). However, patients with uHCC with portal vein tumor thrombosis (PVTT) have a limited response to TT alone. This study evaluated whether combining TT with radiotherapy (TTR) could increase conversion resection rates and improve the prognosis of uHCC with PVTT. A total of 123 patients treated at our institution from 2020-2024 were retrospectively analyzed, comprising 103 patients receiving TT and 20 receiving TTR. The overlap weighting (OW) method was used to minimize bias. Compared with the TT group, patients in the TTR group had a significantly greater early tumor shrinkage rate (85.0% vs. 59.2%, p = 0.029). Moreover, conversion resection rates were significantly higher in the TTR group (65.0% vs. 35.0%, p = 0.012), and the median overall survival (OS) was notably prolonged (median OS not reached vs. 31.9 months, p = 0.031). Following OW adjustment of the data, we obtained similar results. Multivariate analysis confirmed TTR as an independent protective factor for both OS (HR = 0.354, 95% CI = 0.127-0.984, p = 0.046) and the conversion resection rate (OR = 0.261, 95% CI = 0.081-0.838, p = 0.024). Treatment-related adverse events were manageable. Thus, TTR offers an improved conversion resection rate and survival outcomes compared with TT alone in patients with uHCC with PVTT and represents a promising therapeutic strategy.","PeriodicalId":8957,"journal":{"name":"Bioscience trends","volume":" ","pages":"468-478"},"PeriodicalIF":5.0,"publicationDate":"2025-09-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144774683","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

A new strategy of laparoscopic anatomical right hemihepatectomy via a hepatic parenchymal transection-first approach guided by the middle hepatic vein. 肝中静脉引导下经肝实质横断优先入路的腹腔镜解剖性右半肝切除术新策略。

IF 5 4区生物学

Bioscience trends Pub Date : 2025-09-17 Epub Date: 2025-08-08 DOI: 10.5582/bst.2025.01040

Nan You, Yongkun Li, Qifan Zhang, Chaoqun Wang, Ke Wu, Zheng Wang, Qian Ren, Jing Li, Lu Zheng

{"title":"A new strategy of laparoscopic anatomical right hemihepatectomy via a hepatic parenchymal transection-first approach guided by the middle hepatic vein.","authors":"Nan You, Yongkun Li, Qifan Zhang, Chaoqun Wang, Ke Wu, Zheng Wang, Qian Ren, Jing Li, Lu Zheng","doi":"10.5582/bst.2025.01040","DOIUrl":"10.5582/bst.2025.01040","url":null,"abstract":"Laparoscopic anatomical right hemihepatectomy (LARH) is a highly challenging procedure due to the lack of an appropriate surgical approach. This study aimed to investigate the safety and efficacy of LARH via a hepatic parenchymal transection-first approach (HPF) guided by the middle hepatic vein (MHV) (HPFM) to treat hepatocellular carcinoma (HCC) by comparison with the extrahepatic Glissonian approach (EG). Between January 2017 and December 2019, a total of 105 HCC patients who underwent LARH, of whom 48 underwent HPFM, were included in this study. After a 1:1 propensity score matching, 41 LARH-HPFM were compared to 41 LARH-EG. We have analyzed perioperative and oncologic outcomes of the two different operative approaches for HCC treatments. Quality of two operative approaches was defined by textbook outcome (TO). The LARH-HPF group was associated with shorter mean operative time (P = 0.029) and less blood loss (P = 0.023). The LARH-HPFM did not increase the postoperative overall complication rates (P = 0.248) when compared with the LARH-EG. The results of univariable and multivariable analyses indicated that LARH-HPFM provided a clinical benefit for operative time and blood loss. In addition, patients who received LARH-HPFM cumulated more TO criteria (P = 0.017), and achieved higher rate of TO (46.3% vs. 24.4%; 2.68, 95% CI 1.05 - 6.86, P = 0.040) compared with those who received LARH-EG. These findings indicate LARH-HPFM is safe and feasible for HCC with certain advantages over LARH-EG, but there are still many problems worth further exploration.","PeriodicalId":8957,"journal":{"name":"Bioscience trends","volume":" ","pages":"456-467"},"PeriodicalIF":5.0,"publicationDate":"2025-09-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144820487","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Chinese multicenter expert consensus on the diagnosis and treatment of hilar cholangiocarcinoma: 2025 edition. 中国肝门部胆管癌诊治多中心专家共识：2025年版。

IF 5 4区生物学

Bioscience trends Pub Date : 2025-09-17 Epub Date: 2025-08-14 DOI: 10.5582/bst.2025.01233

Sulai Liu, Jinqiong Jiang, Qian Jian, Yingbin Liu, Zhiyong Huang, Yongjun Chen, Chihua Fang, Zhaohui Tang, Lu Wang, Deyu Li, Fuyu Li, Shaoqiang Li, Xuemin Liu, Cuncai Zhou, Yamin Zheng, Heguang Huang, Chen Chen, Xu Chen, Bo Sun, Weimin Yi, Bingzhang Tian, Liansheng Gong, Wei Liu, Feizhou Huang, Jia Luo, Dongde Wu, Shuke Fei, Lixin Xiong, Caixi Tang, Shaojie Li, Yi Yu, Jushi Li, Biao Tang, Yongqing Yang, Xuzhao Gao, Xingguo Tan, Yu Liu, Wei Tang, Bo Jiang, Zhiming Wang, Huihuan Tang, Jinshu Wu, Chuang Peng

{"title":"Chinese multicenter expert consensus on the diagnosis and treatment of hilar cholangiocarcinoma: 2025 edition.","authors":"Sulai Liu, Jinqiong Jiang, Qian Jian, Yingbin Liu, Zhiyong Huang, Yongjun Chen, Chihua Fang, Zhaohui Tang, Lu Wang, Deyu Li, Fuyu Li, Shaoqiang Li, Xuemin Liu, Cuncai Zhou, Yamin Zheng, Heguang Huang, Chen Chen, Xu Chen, Bo Sun, Weimin Yi, Bingzhang Tian, Liansheng Gong, Wei Liu, Feizhou Huang, Jia Luo, Dongde Wu, Shuke Fei, Lixin Xiong, Caixi Tang, Shaojie Li, Yi Yu, Jushi Li, Biao Tang, Yongqing Yang, Xuzhao Gao, Xingguo Tan, Yu Liu, Wei Tang, Bo Jiang, Zhiming Wang, Huihuan Tang, Jinshu Wu, Chuang Peng","doi":"10.5582/bst.2025.01233","DOIUrl":"10.5582/bst.2025.01233","url":null,"abstract":"Hilar cholangiocarcinoma (hCCA) is a malignant tumor originating from the epithelial cells of the bile ducts, and it is characterized by an aggressive nature, complex surgical management, high mortality, and poor prognosis. Despite recent advances in surgical techniques, medical devices, and related technologies, there remains a pressing need to standardize diagnostic and therapeutic pathways to improve treatment outcomes and extend long-term patient survival. To better integrate and refine these standards, this consensus was reached through a national conference held in Changsha, Hunan Province, involving multidisciplinary experts from various regions across China. This collaborative effort, drawing from various medical facilities and academic organizations nationwide, resulted in the reaching of the \"Chinese Multicenter Expert Consensus on the Diagnosis and Treatment of Hilar Cholangiocarcinoma: 2025 Edition\" based on current clinical studies and over 40 years of clinical practice experience in managing hCCA. The consensus provides a comprehensive overview of hCCA, including its epidemiological characteristics, diagnostic and screening methods, pathological features, staging and classification systems, and various treatment modalities, while offering specific and actionable recommendations for clinical practice that highlight well-defined indications for surgical, local, and systemic therapies and that emphasize the importance of multidisciplinary approaches to both diagnostic and therapeutic workflows.","PeriodicalId":8957,"journal":{"name":"Bioscience trends","volume":" ","pages":"379-403"},"PeriodicalIF":5.0,"publicationDate":"2025-09-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144844328","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

A technological convergence in hepatobiliary oncology: Evolving roles of smart surgical systems. 肝胆肿瘤学的技术融合：智能手术系统的演变作用。

IF 5 4区生物学

Bioscience trends Pub Date : 2025-09-17 Epub Date: 2025-08-04 DOI: 10.5582/bst.2025.01047

Xuanci Bai, Runze Huang, Qinyu Liu, Xin Jin, Lu Wang, Wei Tang, Kenji Karako, Weiping Zhu

{"title":"A technological convergence in hepatobiliary oncology: Evolving roles of smart surgical systems.","authors":"Xuanci Bai, Runze Huang, Qinyu Liu, Xin Jin, Lu Wang, Wei Tang, Kenji Karako, Weiping Zhu","doi":"10.5582/bst.2025.01047","DOIUrl":"10.5582/bst.2025.01047","url":null,"abstract":"Cancer remains a major threat to human health, with the incidence of hepatobiliary tumors consistently high. Treatment methods for hepatobiliary tumors include surgical intervention, ablation, embolization, and pharmacological treatments, with surgery being a critical component of systemic treatment for patients with hepatobiliary tumors. Compared to other methods, surgery is the most effective way to remove tumors and improve survival rates, serving as the cornerstone of various treatment strategies. However, the large patient population sometimes burdens traditional surgical oncology. In recent years, rapidly advancing artificial intelligence (AI) technologies, characterized by efficiency, precision, and personalization, align well with the treatment philosophy of oncologic surgery. Increasing studies have shown that AI-assisted surgical oncology outperforms traditional approaches in many aspects. This review, based on machine learning, neural networks, and other AI techniques, discusses the various applications of AI throughout the entire process of hepatobiliary tumor surgical treatment, including diagnostic assistance, surgical decision-making, intraoperative support, postoperative monitoring, risk assessment, and medical education. It offers new insights and directions for the integration and application of AI in oncologic surgery.","PeriodicalId":8957,"journal":{"name":"Bioscience trends","volume":" ","pages":"410-420"},"PeriodicalIF":5.0,"publicationDate":"2025-09-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144774680","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Multimodal treatment of colorectal liver metastases: Where are we? Current strategies and future perspectives. 多模式治疗结直肠癌肝转移：进展如何？当前战略和未来展望。

IF 5.7 4区生物学

Bioscience trends Pub Date : 2025-07-04 Epub Date: 2025-03-18 DOI: 10.5582/bst.2025.01012

Caterina Accardo, Ivan Vella, Fabrizio di Francesco, Sergio Rizzo, Sergio Calamia, Alessandro Tropea, Pasquale Bonsignore, Sergio Li Petri, Salvatore Gruttadauria

{"title":"Multimodal treatment of colorectal liver metastases: Where are we? Current strategies and future perspectives.","authors":"Caterina Accardo, Ivan Vella, Fabrizio di Francesco, Sergio Rizzo, Sergio Calamia, Alessandro Tropea, Pasquale Bonsignore, Sergio Li Petri, Salvatore Gruttadauria","doi":"10.5582/bst.2025.01012","DOIUrl":"10.5582/bst.2025.01012","url":null,"abstract":"Despite the continued high prevalence of colorectal cancer in the Western world, recent years have witnessed a decline in its mortality rate, largely attributable to the sustained advancement of multimodal treatment modalities for metastatic patients. One persisting issue is lack of consensus between different centres and multidisciplinary teams regarding definition of resectability, the duration of chemotherapy treatment, and surgical strategy. This narrative review outlines current multimodal treatment of patients with colon cancer metastatic to the liver and/or lung in different clinical scenarios. Currently, there are multiple multimodal strategies that can be employed to enhance resectability in these patients. These include novel and sophisticated target therapies (such as novel immunotherapeutic modalities and micro RNAs), complex resections utilising parenchyma-sparing techniques, liver transplantation, and cytoreductive strategies in patients for whom a curative option is not feasible. It is the responsibility of the scientific community to establish standardised protocols across different centres, based on the most recent evidence, while maintaining a high degree of personalisation of treatment for each individual patient. It seems likely that artificial intelligence (AI) will play a significant role in achieving this goal.","PeriodicalId":8957,"journal":{"name":"Bioscience trends","volume":" ","pages":"309-327"},"PeriodicalIF":5.7,"publicationDate":"2025-07-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143655943","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

SNRPA promotes hepatocellular carcinoma proliferation and lenvatinib resistance via B7-H6-STAT3/AKT axis by facilitating B7-H6 pre-mRNA maturation. SNRPA通过B7-H6- stat3 /AKT轴促进B7-H6前mrna成熟，促进肝癌增殖和lenvatinib耐药。

IF 5.7 4区生物学

Bioscience trends Pub Date : 2025-07-04 Epub Date: 2025-04-15 DOI: 10.5582/bst.2025.01036

Jiejun Hu, Junhua Gong, Xia Shu, Xin Dai, Dong Cai, Zhibo Zhao, Jinhao Li, Guochao Zhong, Jianping Gong

{"title":"SNRPA promotes hepatocellular carcinoma proliferation and lenvatinib resistance via B7-H6-STAT3/AKT axis by facilitating B7-H6 pre-mRNA maturation.","authors":"Jiejun Hu, Junhua Gong, Xia Shu, Xin Dai, Dong Cai, Zhibo Zhao, Jinhao Li, Guochao Zhong, Jianping Gong","doi":"10.5582/bst.2025.01036","DOIUrl":"10.5582/bst.2025.01036","url":null,"abstract":"The pre-mRNAs splicing is important mechanisms of hepatocellular carcinoma (HCC) progression. Hence, this study aimed to explore the function and corresponding mechanisms of small nuclear ribonucleoprotein polypeptide A (SNRPA), a vital RNAs splicing molecule, in HCC. Here, the University of Alabama at Birmingham CANcer data analysis portal (UALCAN), western blotting, and immunohistochemistry indicated that SNRPA levels were elevated in HCC tissues. Moreover, high expression of SNRPA was correlated with unfavorable clinicopathologic features and poor survival in HCC patients. A series of in vitro and in vivo gain/loss-of-function experiments reported that SNRPA promoted the proliferation of HCC cells. Integrated nanopore full-length cDNA sequencing and RNA-binding protein immunoprecipitation sequencing revealed that B7 homologue 6 (B7-H6) was a potential target of SNRPA. Subsequently, western blotting and flow cytometry showed that SNRPA activated B7-H6-STAT3/AKT signaling axis in HCC cells with promotion of G1-S transition in the cell cycle and inhibition of cell apoptosis. Mechanistically, RNA-binding protein immunoprecipitation and polymerase chain reaction with using exon-exon and exon-intron junction primers revealed that SNRPA facilitated B7-H6 pre-mRNA maturation by binding to it directly and contributing to its intron 2 splicing. Moreover, drug sensitivity test found that SNRPA induced HCC cell resistance to lenvatinib. Finally, restoration experiments demonstrated that the effects of SNRPA on HCC cells relied on B7- H6 expression. Taken together, SNRPA promotes HCC growth and lenvatinib resistance via B7-H6-STAT3/AKT axis through facilitating B7-H6 pre-mRNA maturation by maintaining its intron 2 splicing. Thus, SNRPA may be a promising target for HCC therapy and lenvatinib resistance reversion.","PeriodicalId":8957,"journal":{"name":"Bioscience trends","volume":" ","pages":"337-350"},"PeriodicalIF":5.7,"publicationDate":"2025-07-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143962767","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Integrative neurorehabilitation using brain-computer interface: From motor function to mental health after stroke. 脑机接口综合神经康复：从脑卒中后的运动功能到心理健康。

IF 5.7 4区生物学

Bioscience trends Pub Date : 2025-07-04 Epub Date: 2025-04-17 DOI: 10.5582/bst.2025.01109

Ya-Nan Ma, Kenji Karako, Peipei Song, Xiqi Hu, Ying Xia

{"title":"Integrative neurorehabilitation using brain-computer interface: From motor function to mental health after stroke.","authors":"Ya-Nan Ma, Kenji Karako, Peipei Song, Xiqi Hu, Ying Xia","doi":"10.5582/bst.2025.01109","DOIUrl":"10.5582/bst.2025.01109","url":null,"abstract":"Stroke remains a leading cause of mortality and long-term disability worldwide, frequently resulting in impairments in motor control, cognition, and emotional regulation. Conventional rehabilitation approaches, while partially effective, often lack individualization and yield suboptimal outcomes. In recent years, brain-computer interface (BCI) technology has emerged as a promising neurorehabilitation tool by decoding neural signals and providing real-time feedback to enhance neuroplasticity. This review systematically explores the use of BCI systems in post-stroke rehabilitation, focusing on three core domains: motor function, cognitive capacity, and emotional regulation. This review outlines the neurophysiological principles underpinning BCI-based motor rehabilitation, including neurofeedback training, Hebbian plasticity, and multimodal feedback strategies. It then examines recent advances in upper limb and gait recovery using BCI integrated with functional electrical stimulation (FES), robotics, and virtual reality (VR). Moreover, it highlights BCI's potential in cognitive and language rehabilitation through EEG-based neurofeedback and the integration of artificial intelligence (AI) and immersive VR environments. In addition, it discusses the role of BCI in monitoring and regulating post-stroke emotional disorders via closed-loop systems. While promising, BCI technologies face challenges related to signal accuracy, device portability, and clinical validation. Future research should prioritize multimodal integration, AI-driven personalization, and large-scale randomized trials to establish long-term efficacy. This review underscores BCI's transformative potential in delivering intelligent, personalized, and cross-domain rehabilitation solutions for stroke survivors.","PeriodicalId":8957,"journal":{"name":"Bioscience trends","volume":" ","pages":"243-251"},"PeriodicalIF":5.7,"publicationDate":"2025-07-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143972597","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Liver exposure during laparoscopic right-sided hepatectomy via stretching of the ligamentum teres hepatis: A propensity score matching analysis. 经肝圆韧带拉伸的腹腔镜右侧肝切除术中肝脏暴露：倾向评分匹配分析。

IF 5.7 4区生物学

Bioscience trends Pub Date : 2025-07-04 Epub Date: 2025-04-09 DOI: 10.5582/bst.2025.01044

Keda Song, Yang Xu, Zhongyu Li, Mingyuan Wang, Dong Chen, Yongzhi Zhou, Guangchao Yang, Yong Ma

{"title":"Liver exposure during laparoscopic right-sided hepatectomy via stretching of the ligamentum teres hepatis: A propensity score matching analysis.","authors":"Keda Song, Yang Xu, Zhongyu Li, Mingyuan Wang, Dong Chen, Yongzhi Zhou, Guangchao Yang, Yong Ma","doi":"10.5582/bst.2025.01044","DOIUrl":"10.5582/bst.2025.01044","url":null,"abstract":"One of the challenges of laparoscopic liver resection (LLR) is the exposure of the surgical field. We propose a new surgical approach to better expose the right liver, stretching of the ligamentum teres hepatis (SLTH), and we evaluated its clinical feasibility and limitations through a study analyzing relevant cases. Clinicopathologic data on patients who underwent laparoscopic right partial hepatectomy (LRPH) at our center were retrospectively collected, and subjects were 276 patients with liver space-occupying lesions who met the selection criteria and who underwent the new surgical approach (SLTH) or the conventional surgical approach (no stretching of the ligamentum teres hepatis, or NSLTH). After 1:1 propensity score matching (PSM), 102 patients in each cohort were selected for further analysis. There were no significant differences in the operating time or the duration of postoperative hospitalization between the SLTH cohort and the NSLTH cohort. The duration of detachment of the hepatic parenchyma and the duration of hepatic portal occlusion were significantly shorter in the SLTH cohort than in the NSLTH cohort. The intraoperative blood loss in the SLTH cohort was significantly less than that in the NSLTH cohort. Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) levels were significantly lower in the SLTH cohort than in the NSLTH cohort on day 5 postoperatively. Results confirmed that SLTH is a simple, safe, effective, and highly reproducible technique for the treatment of LRPH. SLTH may help to perform LRPH by increasing the level of laparoscopic exposure of the right liver and reducing bleeding and operating time.","PeriodicalId":8957,"journal":{"name":"Bioscience trends","volume":" ","pages":"361-367"},"PeriodicalIF":5.7,"publicationDate":"2025-07-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143971380","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0